GILD GILEAD SCIENCES, INC.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0000882095
AI RATING
BUY
78% Confidence

Investment Thesis

Gilead demonstrates exceptional profitability (29% net margin, 85.2% gross margin) and outstanding cash generation ($2.4B free cash flow, 34.9% FCF margin), providing strong financial stability. However, flat net income growth (0% YoY) despite 2.4% revenue growth and modest earnings expansion suggest the company faces growth headwinds or margin pressures that warrant monitoring.

Strengths

  • + Exceptional profitability with 29% net margin and 85.2% gross margin demonstrates pricing power and operational leverage
  • + Outstanding free cash flow generation of $2.4B (34.9% FCF margin) provides capital for R&D, debt reduction, and shareholder returns
  • + Strong balance sheet with manageable leverage (0.94x Debt/Equity) and excellent interest coverage (10.2x) ensures financial stability
  • + Solid liquidity position with current ratio of 1.97x and $7.6B cash reserves

Risks

  • ! Flat net income growth (0% YoY) despite 2.4% revenue growth indicates margin compression or operational challenges
  • ! Modest revenue growth of 2.4% suggests potential pipeline weakness or market maturation in core products
  • ! Elevated debt load of $22.2B limits financial flexibility and creates refinancing risk in higher rate environment
  • ! Low returns on equity (8.6%) and assets (3.6%) suggest suboptimal capital efficiency relative to large asset base

Key Metrics to Watch

Financial Metrics

Revenue
7.0B
Net Income
2.0B
EPS (Diluted)
$1.61
Free Cash Flow
2.4B
Total Assets
56.3B
Cash
7.6B

Profitability Ratios

Gross Margin 85.2%
Operating Margin 37.2%
Net Margin 29.0%
ROE 8.6%
ROA 3.6%
FCF Margin 34.9%

Balance Sheet & Liquidity

Current Ratio
1.97x
Quick Ratio
1.77x
Debt/Equity
0.94x
Debt/Assets
0.0%
Interest Coverage
10.18x
Long-term Debt
22.2B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T10:49:19.328183 | Data as of: 2026-03-31 | Powered by Claude AI